Vimizim Voucher A Result Of BioMarin’s Late Request, FDA Flexibility

Sponsors of rare pediatric disease treatments should be buoyed by news that FDA’s Office of Orphan Products Development liberally interpreted the FDASIA language that requires priority review vouchers be given only when an indication is limited to a pediatric population.